Knowledge Library Prototype
FDA Approvals & Medication Safety
Prototype collection covering FDA approvals, new indications, safety communications, recalls, shortages, labeling updates, biosimilars, generics, and AJPPS-related regulatory research.
Featured AJPPS Research
Placeholder for AJPPS articles related to medication safety, regulatory science, drug approvals, pharmacovigilance, and patient safety.
Latest Regulatory Intelligence
Reserved for approved RSS/API content from FDA and other trusted regulatory sources.
FDA Drug Updates
- BsUFA IV: Fiscal Years 2028-2032
by FDA on 07/16/2026 at 5:00 pmOn September 30, 2022, the President signed into law the FDA User Fee Reauthorization Act of 2022.
- MantroForce - 729021 - 06/17/2026by FDA on 07/16/2026 at 4:35 pm
Unapproved New Drugs/Misbranded
- CDER Small Business & Industry Assistance (SBIA)by FDA on 07/16/2026 at 4:34 pm
A Comprehensive Resource for Information on Human Drug Development in Regulation
- Wholesale Peptide - 729447 - 06/17/2026by FDA on 07/16/2026 at 4:22 pm
Unapproved New Drugs/Misbranded
- Texinkart Inc. - 729046 - 06/17/2026by FDA on 07/16/2026 at 4:20 pm
Unapproved New Drugs/Misbranded
Recalls & Safety Alerts
- Feed has no items.
Clinical and Practice Relevance
Future summaries should translate regulatory updates into implications for pharmacists, pharmaceutical scientists, educators, students, and industry professionals.
Related Collections
- Regulatory Science Intelligence
- Clinical Pharmacy
- Pharmacogenomics Intelligence
- Drug Delivery & Pharmaceutics